Table 1.
Outcomes for patients without FLT3-ITD and those with FLT3-ITDpos according to cooccurring mutation risk groups
| Non-FLT3-ITD |
FLT3-ITDpos |
P value | |||
|---|---|---|---|---|---|
| N | %, 95 CI | N | %, 95 CI | ||
| FR mutations | |||||
| 5-year OS | 931 | 81.5%, 78.9%-83.9% | 122 | 76.9%, 68.1%-83.5% | .357 |
| 5-year EFS | 931 | 65.1%, 61.9%-68.1% | 122 | 64.0%, 54.6%-71.9% | .547 |
| 5-year relapse risk from EOI1 | 807 | 25.3%, 22.3%-28.4% | 109 | 25.5%, 17.6%-34.1% | .506 |
| INT risk mutations | |||||
| 5-year OS | 1502 | 53.2%, 50.6%-55.8% | 136 | 55.9%, 46.8%-63.9% | .372 |
| 5-year EFS | 1502 | 38.4%, 35.9%-40.9% | 136 | 41.9%, 33.4%-50.1% | .230 |
| 5-year relapse risk from EOI1 | 1064 | 47.4%, 44.3%-50.4% | 94 | 41.1%, 30.9%-51.0% | .104 |
| PR mutations | |||||
| 5-year OS | 136 | 49.1%, 40.2%-57.4% | 206 | 38.7%, 31.8%-45.5% | .093 |
| 5-year EFS | 136 | 29.7%, 22.1%-37.6% | 206 | 22.2%, 16.7%-28.2% | .065 |
| 5-year relapse risk from EOI1 | 90 | 53.5%, 42.4%-63.3% | 98 | 59.8%, 49.2%-63.9% | .323 |
Cooccurring mutation risk groups stratified according to favorable (NPM1, CEBPA, RUNX1-RUNX1T1, CBFB-MYH11), poor (WT1, UBTF, NUP98-NSD1), and intermediate (all other) risk mutations.
EOI1, endo of induction 1.